BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19793373)

  • 1. Right ventricular dysfunction and the incidence of implantable cardioverter-defibrillator therapies.
    Aktas MK; Kim DD; McNitt S; Huang DT; Rosero SZ; Hall BW; Zareba W; Daubert JP
    Pacing Clin Electrophysiol; 2009 Dec; 32(12):1501-8. PubMed ID: 19793373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
    Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of appropriate defibrillator therapy in heart failure patients treated with cardiac resynchronization therapy.
    Soliman OI; Theuns DA; van Dalen BM; Vletter WB; Nemes A; Jordaens LJ; Balk AH; Ten Cate FJ; Geleijnse ML
    Am J Cardiol; 2010 Jan; 105(1):105-11. PubMed ID: 20102900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Right ventricular pacing is an independent predictor for ventricular tachycardia/ventricular fibrillation occurrence and heart failure events in patients with an implantable cardioverter-defibrillator.
    Gardiwal A; Yu H; Oswald H; Luesebrink U; Ludwig A; Pichlmaier AM; Drexler H; Klein G
    Europace; 2008 Mar; 10(3):358-63. PubMed ID: 18308756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure.
    Elming MB; Hammer-Hansen S; Voges I; Nyktari E; Raja AA; Svendsen JH; Pehrson S; Signorovitch J; Køber LV; Prasad SK; Thune JJ
    Circ Arrhythm Electrophysiol; 2019 Mar; 12(3):e007022. PubMed ID: 30866666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter defibrillator therapy for patients with less severe left ventricular dysfunction.
    Exner DV
    Curr Opin Cardiol; 2009 Jan; 24(1):61-7. PubMed ID: 19077818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
    Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
    Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function.
    Schaer BA; Ammann P; Sticherling C; Zellweger MJ; Cron TA; Osswald S
    Int J Cardiol; 2006 Mar; 108(1):26-30. PubMed ID: 16516695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.
    Healey JS; Hallstrom AP; Kuck KH; Nair G; Schron EP; Roberts RS; Morillo CA; Connolly SJ
    Eur Heart J; 2007 Jul; 28(14):1746-9. PubMed ID: 17283003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
    Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
    Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.
    Corrado D; Leoni L; Link MS; Della Bella P; Gaita F; Curnis A; Salerno JU; Igidbashian D; Raviele A; Disertori M; Zanotto G; Verlato R; Vergara G; Delise P; Turrini P; Basso C; Naccarella F; Maddalena F; Estes NA; Buja G; Thiene G
    Circulation; 2003 Dec; 108(25):3084-91. PubMed ID: 14638546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II).
    Greenberg H; Case RB; Moss AJ; Brown MW; Carroll ER; Andrews ML;
    J Am Coll Cardiol; 2004 Apr; 43(8):1459-65. PubMed ID: 15093884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients.
    Pietrasik G; Goldenberg I; McNitt S; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2007 Feb; 18(2):181-4. PubMed ID: 17338766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.